Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral abuse-deterrent formulation of ER morphine sulfate tablets (morphine ARER [abuse-resistant extended-release], MorphaBondTM ER) resists physical manipulation and chemical extraction, forms a nonsyringeable material in liquid environments, and retains its ER characteristics despite manipulation. Morphine ARER is formulated with multiple overlapping physiochemical barriers instead of antagonists or aversive agents to deter misuse and abuse. When crushed and taken intranasally, morphine ARER has a 40% lower mean maximum drug-liking score than crushed intranasal morphine ER.
Explore related content and topics
Blog
A Caregiver’s Experience with Glioblastoma
Glioblastoma (GBM) is one of the most complex, deadly, treatment-resistant cancers that accounts for 48% of all primary malignant brain tumors. In…
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Newsletter
Industry Watch
In the third week of November, Industry Watch brings you news on the role played by gut microbiota in conditions such as Parkinson’s, MS, and…